Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.
OBJECTIVE
To examine cost and mortality differences in postmenopausal women with HR(+)/HER2(-) advanced breast cancer.


METHODS
Using claims data (2007-2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified.


RESULTS
Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents. Adjusted per patient per month costs for early-recurrent patients were US$13,404, versus US$9955 (de novo) and US$9721 (late-recurrent; p = 0.02). Early-recurrent patients' risk of death was twice that of de novo patients (p = 0.02).


CONCLUSIONS
Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.
Senior Researcher, Optum, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA.
Nicole M
NM
Engel-Nitz
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Yanni
Y
Hao
Senior Researcher, Optum, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA.
Laura K
LK
Becker
Senior Researcher, Optum, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA.
Randall
R
Gerdes
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000191:economics* / Q000401:mortality* / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000191:economics* / Q000401:mortality*; D018719:Erb-b2 Receptor Tyrosine Kinases; D012189:Retrospective Studies; D016019:Survival Analysis; D014481:United States / Q000453:epidemiology
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases
HER2-; breast cancer; claims analysis; costs; estrogen receptor positive; hormone receptor positive; mortality; retrospective analysis